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Hypertension-misattributed
kidney disease in African
Americans
Karl L. Skorecki1 and Walter G. Wasser2
Lipkowitz et al. extend the African American Study of Kidney Disease
and Hypertension to the level of genetic epidemiology, in a
case–control study design. Analysis of genotypes at the APOL1 kidney
disease risk region supports a paradigm shift in which genetic risk is
proximate to both kidney disease and hypertension. The findings
mandate urgency in clarifying mechanisms whereby APOL1 region risk
variants interact with environmental triggers to cause progressive
kidney disease accompanied by dangerous hypertension.
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Nephrologists in North America have
long observed that African Americans
with hypertension-associated kidney
disease display a poor kidney-protective
response to medications that effectively
lower arterial blood pressure and a
more rapid pattern of kidney disease
progression compared with their non-
African counterparts. The chicken-and-
egg conundrum of hypertension as a
cause of nondiabetic, secondary kidney
disease or a consequence of primary
kidney disease was effectively addressed
by the findings of the African American
Study of Kidney Disease and Hyperten-
sion (AASK) trial and cohort follow-up
studies.1 African-ancestry participants
in this landmark comparative thera-
peutic intervention trial, receiving
antihypertensive agents, including
angiotensin-converting enzyme inhibi-
tors, appeared not to accrue the benefit
expected from effective control of
systemic arterial blood pressure, in
terms of progression to end points
indicative of chronic kidney disease.1
(A subgroup of subjects with urine
protein-to-creatinine-excretion ratios
greater than 0.22 g may have shown
relative benefit from angiotensin-con-
verting enzyme inhibitor therapy.)
Although not directly comparable,
observational studies in population
groups without sufficient representa-
tion of people of recent African
ancestry supported the conventional
wisdom of a kidney-protective benefit
from antihypertensive therapy, even in
nondiabetic kidney disease.2 In con-
trast, the AASK studies strongly suggest
that an underlying factor(s) other
than hypertension per se might be
responsible for chronic kidney disease
risk with hypertension as an accompani-
ment, at least among African Americans.
The epidemiologic inference is further
strengthened by the strikingly different
histopathology in the kidneys of
African- versus non-African-ancestry
people clinically labeled with ‘hyper-
tensive nephrosclerosis.’3 The foregoing
would not be expected if a single disease
entity were present.
Lipkowitz and colleagues4 (this
issue) now provide elegant further
resolution at the molecular epidemio-
logic level, by relating the AASK
findings to the rapidly evolving story
of powerful kidney disease risk variants
at a chromosome 22q genomic region
containing the genes MYH9 and
APOL1. Although some questions
remain about the former, the finding
of an association of two DNA sequence
risk variants (designated as the G1 and
G2 alleles) at the APOL1 gene with
certain major forms of nondiabetic
kidney disease has transformed our
understanding of population ancestry
disparities in kidney disease risk.5–7
Evolutionary adaptive pressures
related to a past survival advantage in
the face of a potentially lethal pathogen
(Trypanosoma brucei rhodesiense) have
resulted in the rise to high frequency
of these two APOL1 alleles in the
parental populations of people from
many regions of sub-Saharan Africa.
Unfortunately, these same alleles are
strongly associated with kidney disease.
Thus, for example, the overall risk
of developing nondiabetic end-stage
kidney disease not attributable to
known mendelian genetic or anatomic
kidney disease may be increased
more than threefold in the presence of
two risk alleles.7 Furthermore, even the
presence of one G1 risk allele may
accelerate the onset of end-stage kidney
disease.8–10 Among the etiologic entities
that contribute the highest odds ratios
(ORs) are HIV-associated nephropathy
(OR, 29; 95% confidence interval (CI),
13–68) and primary non-monogenic
focal segmental glomerulosclerosis
(OR, 17; 95% CI, 11–26),9 both
diseases generally characterized by
marked glomerular-range proteinuria.
Clearly the vast majority of progressive
nondiabetic chronic kidney disease in
African Americans does not fit either of
these latter two classical etiologic
presentations, and is often accompan-
ied by hypertension with no protei-
nuria or only low-grade proteinuria. In
these cases, the default diagnosis had
been ‘hypertensive nephrosclerosis,’
comprising more than 35% of the
etiologic category in the US Renal
Data System end-stage kidney disease
registry for African Americans.11
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A major conceptual transformation
with important further practical impli-
cations is now clearly in order in light
of Lipkowitz et al.’s insightful and
informative population genetic and
case–control addition to the AASK
trials. Lipkowitz et al.4 report the G1
and G2 allelic state (as well as geno-
types of several other sites in the region
and at informative genome-wide ancestry
markers) in 675 AASK cases and 618
non-nephropathic controls. The cases
were African Americans recruited
throughout the United States, between
the ages of 18 and 70 years with
diastolic blood pressure higher than
95mmHg and a measured iothalamate
glomerular filtration rate between 20
and 65ml/min/1.78m2, indicative of
chronic kidney disease. Since non-
nephropathic controls were not part
of the AASK cohort, these African-
American subjects were recruited at
Wake Forest School of Medicine and
fulfilled the enrollment criteria of
serum creatinine concentrations less
than 1.5mg/dl in men and less than
1.3mg/dl in women.
Case–control analysis showed a
highly significant association of the G1
genotype and the AASK label of ‘hy-
pertensive nephropathy’ under a reces-
sive inheritance model. While ORs are
higher in HIV-associated nephropathy
and focal segmental glomerulosclerosis
as noted above, the finding of an OR of
2.57 (95% CI, 1.85–3.55), with P¼ 1.4–8
despite the relatively small sample size,
can be considered a vindication of the
currently much maligned ‘common
disease, common variant’ formulation.
The clinical phenotype of hypertension
with chronic kidney disease affects
millions worldwide, and the associated
G1 allele frequencies are well into the
‘common’ range in the population of
interest (51% of African Americans
carry at least one risk allele7). The
association of APOL1 G1 was stronger
still with more advanced kidney disease
at AASK baseline (urine protein-to-
creatinine-excretion ratio 40.6 g/g)
(OR, 6.29; 95% CI, 3.92–10.11;
P¼ 2.6–14), and with serum creatinine
greater than 3mg/dl during follow-up
(OR, 4.61; 95% CI, 3.14–6.76;
P¼ 5.6–15). As in previous studies,
associations with the lower-frequency
G2 risk allele were more difficult to
prove—perhaps for statistical or possi-
bly biological reasons.8,9
Lipkowitz et al.4 took full advantage
of the treatment arms of the original
AASK intervention trial, which used a
two-by-three factorial design to
examine the effects of medication class
(calcium blocker, angiotensin-conver-
ting enzyme inhibitor, and beta-
blocker), and of intensity of blood
pressure control (‘usual,’ mean arterial
pressure o102–107mmHg, versus
‘low,’ mean arterial pressure o92).
Importantly, there was no observable
influence of APOL1 genotype on
achieved blood pressure in the usual-
and low-intensity arms. Disappointin-
gly perhaps, multiple analyses,
including a general linear model, did
not demonstrate a significant interact-
ion of age- and sex-adjusted medi-
cation-class group, nor of intensity of
blood pressure control arm, with the
APOL1 allelic state, under a recessive
model. In other words, in contrast to
conclusions from recent kidney graft
survival studies,12 African-ancestry
people with no APOL1 risk variants
cannot yet be approached with
treatment paradigms that seem to
apply to non-African-ancestry counter-
parts. Although the relative benefit
reported for angiotensin-converting
enzyme inhibitors in the original non-
genotyped AASK trial and cohort
studies for proteinuric subjects
(protein-to-creatinine ratio 40.22 g/g)
was not replicated in the current study,
it may be premature to dismiss a
role for APOL1 genotyping in guiding
antihypertensive medication choice
and usage in African-ancestry
populations. It should also be kept in
mind that in the AASK trial, patients
with low levels of proteinuria who were
randomly assigned to the low blood
pressure group, experienced worse
outcomes compared to the usual
blood pressure group.13
The study by Lipkowitz et al.4 also
made a valiant attempt to address the
crucial question of whether or not
hypertension, in the absence of
clinically overt kidney disease, may
also be associated with the APOL1
kidney disease risk region. The
investigators were able to question 409
of the 618 controls, and among these,
171 (41.7%) recalled having been told
of hypertension by their health-care
professionals or reported using
antihypertensive medication. In
particular, comparison of subsets of
controls phenotyped in this manner for
hypertension status showed no relation
to APOL1 genotype. This provides a
tentative suggestion that hypertension
in the absence of chronic kidney disease
in African Americans may not be related
to a clinical entity of subclinical
APOL1 associated kidney disease.
However, an important caveat is the
possibility that in the absence of kidney
biopsy, large numbers of people might
exist with subclinical forms of APOL1-
associated primary kidney disease with
hypertension as a first clinical
manifestation. Since it is unlikely that
kidney biopsies would be performed,
an appropriate clinical study should be
designed to address this question. This
new study should include large
numbers of participants with careful
and objective determination of blood
pressure status, no other evidence of
kidney disease at enrollment, and long-
term follow-up with tailored exami-
nation of the benefit of the antihyper-
tensive therapy conditioned to APOL1
genotype in the African-ancestry popu-
lation.
Perhaps the most appropriate venue
for such a study is the African con-
tinent, where appreciation of hyperten-
sion accompanied by life-threatening
complications is growing, and progres-
sive chronic kidney disease without
recourse to kidney replacement therapy
is the rule (Figure 1). Keeping in mind
the need to effectively treat hyperten-
sion to prevent nonrenal complications
as well, in such a setting it becomes
mandatory to have a comprehensive
understanding of the possible kidney
origin of hypertension (including
APOL1 risk allele nephropathy), and
the relationship between preferred
modalities of treatment for hyperten-
sion and preservation of kidney
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integrity. Moreover, the genetic epide-
miology should be more straight-
forward in the absence of the vari-
able degree of non-sub-Saharan African
admixture seen in other study
venues. For example, recently released
guidelines of the British Hypertension
Society provide very clear directives
that categorize African-ancestry sub-
jects together as a homogeneous group
in terms of recommendation of calcium
blockers as the preferred initial anti-
hypertensive modality (http://www.nice.
org.uk/nicemedia/live/13561/56015/56015.
pdf). In this regard, it will be important
to know whether APOL1 genotype
should be an additional guiding factor
in making the antihypertensive choice
that is most appropriate for a given
person.
So too, at the level of clinical trial
design, the genetic epidemiology com-
ponent that Lipkowitz et al. have so
importantly added in the aftermath of
the AASK trial and cohort study should
now become part and parcel of future
clinical trials in this and other areas. It
is likely that clinical trials that do not
incorporate the technical capacity, and
meet the regulatory standards for DNA
analysis, will fall short of being able to
reach meaningful conclusions. In the
case of observational epidemiology, this
has been amply proven by the recent
mendelian randomization that disso-
ciated the causative relationship be-
tween high-density lipoprotein levels
and coronary disease risk.14 With
appropriately designed, prospective,
interventional trials, stratification by
categories delineated with the tools of
population genetics will likely become
the standard approach unifying con-
ventional and genetic epidemiology.
Another interesting feature of the
study by Lipkowitz et al.4 is the strong
association of APOL1 G1 risk allelic
state with kidney disease that is
distinctly not characterized by high-
grade proteinuria. This raises the
question of the other genetic or
environmental factors that determine
whether the patient with two parental
risk alleles at APOL1 will develop no
disease throughout his or her lifetime,
non-proteinuric chronic kidney disease
accompanied by hypertension, or one
of the high-grade proteinuria glomeru-
lopathies. This question brings us
back to the urgent need to understand
the biology of APOL1 risk allele-
associated kidney injury. As the
authors point out, this may be the
only comprehensive and definitive
means of developing effective preven-
tive and therapeutic interven-
tions that preserve kidney function, if
blood pressure control—as important
as it is for prevention of other poten-
tially catastrophic cardiovascular
complications—proves simply not to
offer kidney protection in the at-risk
African-ancestry population.
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Dialysis time, survival, and
dose-targeting bias
John T. Daugirdas1
Dialysis time is increasingly being appreciated as an important measure
of dialysis adequacy. Increased dialysis time leads to better control of
volume excess, to reduced occurrence of intradialytic hypotension, and
to better control of serum phosphorus. Nevertheless, the amount of
benefit obtainable by moderate increases in dialysis time in patients
following a three-times-per-week schedule has not been well
established, and the analysis is confounded by associations between
prescribed and/or delivered dialysis time and factors related to patient
mortality.
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In this issue of Kidney International,
analyzing a cohort of prevalent patients
being dialyzed mostly three times per
week with 3- to 5-hour session lengths,
Flythe et al.1 report on the association
between prescribed dialysis treatment
time and survival. They found a subs-
tantial mortality increase associated with
slightly shorter prescribed session length.
Controlling for body size is impor-
tant when analyzing effects of compo-
nents of dialysis treatment on survival,
because body size and dialysis prescrip-
tion normally are somewhat con-
founded: one main target of dialysis is
to achieve a minimum urea reduction
ratio. In small patients a given urea
reduction ratio can more easily be
achieved with a relatively short dialysis
session length; thus, smaller patients
and patients with low total body water
(such as women) typically will be
dialyzed for shorter periods than larger
patients and, especially, large men.
For reasons not yet clear, smaller
hemodialysis patients have a markedly
increased mortality. If no adjustment is
made for body size, when mortality is
found to be increased in patients
receiving shorter dialysis treatments, it
is not clear whether the effect is due to
treatment time alone or was partly or
completely mediated by body size. On
the other hand, it remains possible that
the shorter treatment time usually
given to smaller patients is causally
related to their increased mortality risk,
and in this case, adjusting the outcomes
analysis for body size might result in an
underestimation of the true risk of
shorter treatments.
The usual method of adjusting for
body size is to consider some measure of
body size, be it weight, anthropometric
estimates of total body water or body
surface area, volume, or body mass
index, as a covariate. Flythe et al.1 used
a matching strategy, in which patients of
a given size being prescribed a dialysis
time less than 4h were matched with
similar-sized patients being prescribed a
dialysis session longer than 4h. Secondary
matching by age, sex, and vascular access
type also was done. When mortality rates
in the less-than-4-hour and more-than-4-
hour groups were compared, there was a
very substantial difference in mortality,
with the group being prescribed less than
4h (mean delivered time, 201min) having
a 26% higher mortality than the size-
matched patients undergoing the
longer treatments (mean delivered
time, 240min).
The concept that dialysis time per se
might be an important measure of
dialysis adequacy, beyond urea reduc-
tion ratio or urea Kt/V, is an old idea
that has been rediscovered and is
gaining increasing traction. Because
urea is a small, highly diffusible mole-
cule, urea can be rapidly removed from
the body by high-efficiency dialysis.
This is true especially in smaller
patients, women, and children, in
whom the volumes of distribution of
urea are relatively small. With short,
rapid dialysis, however, it is more
difficult to remove partially seques-
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